The role of ACT score in mepolizumab discontinuation

References

• López-Tiro J, Contreras-Contreras A, Rodríguez-Arellano ME, Costa-Urrutia P. Economic burden of severe asthma treatment: a real-life study. World Allergy Organ J. 2022;15(7):100662. doi:10.1016/j.waojou.2022.100662.
   PubMed Web of Science ®Google Scholar
• Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023;11(7):589. doi:10.1016/S2213-2600(23)00230-8.
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, Liu MC, Martin N, Papi A, Roufosse F, et al. From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022;77(3):778–797. doi:10.1111/all.15056.
   PubMed Web of Science ®Google Scholar
• Fala L. Nucala (Mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9(Spec Feature):106–110.
   PubMedGoogle Scholar
• Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201–1212. doi:10.1002/pds.4932.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, et al. Real-world effectiveness and the characteristics of a "super-responder" to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042.
   PubMed Web of Science ®Google Scholar
• van Toor JJ, van der Mark SC, Kappen JH, In ‘t Veen J, Braunstahl GJ. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2021;58(5):651–658. doi:10.1080/02770903.2020.1723623.
   PubMed Web of Science ®Google Scholar
• Kroes JA, Alfonso-Cristancho R, Bansal AT, Berret E, Bieksiene K, Bourdin A, Brussino L, Canhoto D, Cardini C, Celik G, et al. Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. ERJ Open Res. 2023;9(2):00745–2022. doi:10.1183/23120541.00745-2022.
   PubMedGoogle Scholar
• Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019.
   PubMed Web of Science ®Google Scholar
• Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2021;58(1):79–84. doi:10.1080/02770903.2019.1658208.
   PubMed Web of Science ®Google Scholar
• Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140(6):1509–1518. doi:10.1016/j.jaci.2017.10.005.
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI.
   PubMed Web of Science ®Google Scholar
• Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162):210067. doi:10.1183/16000617.0067-2021.
   PubMed Web of Science ®Google Scholar
• Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169–1179. doi:10.1016/j.jaci.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Litonjua AA, Sparrow D, Celedon JC, DeMolles D, Weiss ST. Association of body mass index with the development of methacholine airway hyperresponsiveness in men: the normative aging study. Thorax. 2002;57(7):581–585. doi:10.1136/thorax.57.7.581.
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. doi:10.1016/S2213-2600(21)00097-7.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Pelaia G, Maglio A, Tinello C, Gallelli L, Lombardo N, et al. Pathobiology of type 2 inflammation in asthma and nasal polyposis. J Clin Med. 2023;12(10)
   Web of Science ®Google Scholar